X4 Pharmaceuticals Files 8-K Report
Ticker: XFOR · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Other Events
TL;DR
X4 Pharma dropped an 8-K, likely with news. Check it.
AI Summary
On April 5, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is located at 61 North Beacon Street, Boston, MA.
Why It Matters
This filing signals a material event or change for X4 Pharmaceuticals, Inc., requiring disclosure to investors and the public.
Risk Assessment
Risk Level: medium — An 8-K filing indicates a significant event, which could be positive or negative, thus carrying a medium level of risk until the details are understood.
Key Numbers
- 001-38295 — Commission File Number (Identifies the company's filing with the SEC.)
- 27-3181608 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- April 5, 2024 (date) — Date of Report
- 61 North Beacon Street, Boston, Massachusetts 02134 (location) — Principal executive offices address
- 001-38295 (other) — Commission File Number
- 27-3181608 (other) — IRS Employer Identification No.
FAQ
What specific event triggered this 8-K filing?
The filing is categorized under 'Other Events' and does not specify the exact event in the provided header information.
When was this report filed?
The report was filed on April 5, 2024.
What is the principal executive office address for X4 Pharmaceuticals, Inc.?
The principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
What is the company's Commission File Number?
The Commission File Number is 001-38295.
What is the IRS Employer Identification Number for X4 Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 27-3181608.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-04-05 16:30:13
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
- $1.00 — per share ("Common Stock") close above $1.00 per share pursuant to Nasdaq Listing Ru
Filing Documents
- xfor-20240405.htm (8-K) — 26KB
- 0001628280-24-015059.txt ( ) — 152KB
- xfor-20240405.xsd (EX-101.SCH) — 2KB
- xfor-20240405_lab.xml (EX-101.LAB) — 23KB
- xfor-20240405_pre.xml (EX-101.PRE) — 13KB
- xfor-20240405_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on November 13, 2023, X4 Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the requirement that the bid price for the Company's common stock, par value $0.001 per share ("Common Stock") close above $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the price of the Company's Common Stock had closed below $1.00 per share for 30 consecutive business days, and that the Company had 180 days to regain compliance with the Bid Price Rule. On April 5, 2024, the Staff notified the Company that, as of April 5, 2024, the Company had regained compliance with the Bid Price Rule and that the matter is now closed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: April 5, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer